These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16135645)

  • 1. Complications from olanzapine in a mentally healthy patient.
    West JC; Brasington SJ
    Am J Psychiatry; 2005 Sep; 162(9):1756. PubMed ID: 16135645
    [No Abstract]   [Full Text] [Related]  

  • 2. Metformin plus sibutramine for olanzapine-associated weight gain and metabolic dysfunction in schizophrenia: a 12-week double-blind, placebo-controlled pilot study.
    Baptista T; Uzcátegui E; Rangel N; El Fakih Y; Galeazzi T; Beaulieu S; de Baptista EA
    Psychiatry Res; 2008 May; 159(1-2):250-3. PubMed ID: 18374423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypertriglyceridemia associated with direct effects of olanzapine rather than with weight gain: a case report.
    Markham-Abedi C; de Leon J
    J Clin Psychiatry; 2006 Sep; 67(9):1473-4. PubMed ID: 17017841
    [No Abstract]   [Full Text] [Related]  

  • 5. Medication-induced weight gain and dyslipidemia in patients with schizophrenia.
    Fenton WS; Chavez MR
    Am J Psychiatry; 2006 Oct; 163(10):1697-704; quiz 1858-9. PubMed ID: 17012676
    [No Abstract]   [Full Text] [Related]  

  • 6. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
    McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
    J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia.
    Casey DE; Haupt DW; Newcomer JW; Henderson DC; Sernyak MJ; Davidson M; Lindenmayer JP; Manoukian SV; Banerji MA; Lebovitz HE; Hennekens CH
    J Clin Psychiatry; 2004; 65 Suppl 7():4-18; quiz 19-20. PubMed ID: 15151456
    [No Abstract]   [Full Text] [Related]  

  • 8. Is olanzapine a brain-sparing medication?
    Joober R; Schmitz N; Malla A; Sengupta S; Karma S
    Arch Gen Psychiatry; 2006 Nov; 63(11):1292. PubMed ID: 17088510
    [No Abstract]   [Full Text] [Related]  

  • 9. Olanzapine and weight gain.
    Isaac MB; Isaac MT
    Am J Psychiatry; 2005 Sep; 162(9):1764-5; author reply 1765. PubMed ID: 16135655
    [No Abstract]   [Full Text] [Related]  

  • 10. When essential medications provoke new health problems: the metabolic effects of second-generation antipsychotics.
    Stein K
    J Am Diet Assoc; 2010 Jul; 110(7):992-1001. PubMed ID: 20630154
    [No Abstract]   [Full Text] [Related]  

  • 11. Aripiprazole improves metabolic adversity in olanzapine-treated schizophrenic patients.
    Chen CH; Huang MC; Lu ML
    J Clin Psychopharmacol; 2007 Oct; 27(5):516-7. PubMed ID: 17873689
    [No Abstract]   [Full Text] [Related]  

  • 12. Weight gain and metabolic syndrome among young patients on antipsychotic medication: what do we know and where do we go?
    Eapen V; John G
    Australas Psychiatry; 2011 Jun; 19(3):232-5. PubMed ID: 21682621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Olanzapine-induced weight gain: chronic infusion using osmotic minipumps does not result in stable plasma levels due to degradation of olanzapine in solution.
    van der Zwaal EM; Luijendijk MC; Adan RA; la Fleur SE
    Eur J Pharmacol; 2008 May; 585(1):130-6. PubMed ID: 18378227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
    Vieweg WV; Sood AB; Pandurangi A; Silverman JJ
    Acta Psychiatr Scand; 2005 Mar; 111(3):177-84. PubMed ID: 15701101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Olanzapine metabolic side effects: a weight gain issue?
    Carulli L; Mazzi F; Rondinella S; Bertolotti M
    Intern Emerg Med; 2008 Sep; 3(3):237-40. PubMed ID: 18369533
    [No Abstract]   [Full Text] [Related]  

  • 16. Olanzapine and pediatric bipolar disorder: evidence for efficacy and safety concerns.
    McClellan JM
    Am J Psychiatry; 2007 Oct; 164(10):1462-4. PubMed ID: 17898331
    [No Abstract]   [Full Text] [Related]  

  • 17. Weight Gain While Switching from Polypharmacy to Ziprasidone: A Case Report.
    Lee CP; Chen AP; Juang YY
    Clin Schizophr Relat Psychoses; 2015; 9(3):141-4. PubMed ID: 23644168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Factors associated with weight gain with olanzapine.
    Gaur N; Grover S
    World J Biol Psychiatry; 2010 Mar; 11(2):156-7. PubMed ID: 20128715
    [No Abstract]   [Full Text] [Related]  

  • 20. [Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].
    Birkás Kováts D; Palik E; Faludi G; Cseh K
    Neuropsychopharmacol Hung; 2005 Sep; 7(3):132-9. PubMed ID: 16493877
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.